BRPI0910461B8 - hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso - Google Patents

hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso

Info

Publication number
BRPI0910461B8
BRPI0910461B8 BRPI0910461A BRPI0910461A BRPI0910461B8 BR PI0910461 B8 BRPI0910461 B8 BR PI0910461B8 BR PI0910461 A BRPI0910461 A BR PI0910461A BR PI0910461 A BRPI0910461 A BR PI0910461A BR PI0910461 B8 BRPI0910461 B8 BR PI0910461B8
Authority
BR
Brazil
Prior art keywords
production method
stimulating hormone
follicle stimulating
pharmaceutical composition
recombinant follicle
Prior art date
Application number
BRPI0910461A
Other languages
English (en)
Inventor
Plaksin Daniel
Cottingham Ian
Boyd White Richard
Original Assignee
Ferring Int Center Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39717519&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0910461(B8) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ferring Int Center Sa filed Critical Ferring Int Center Sa
Publication of BRPI0910461A2 publication Critical patent/BRPI0910461A2/pt
Publication of BRPI0910461A8 publication Critical patent/BRPI0910461A8/pt
Publication of BRPI0910461B1 publication Critical patent/BRPI0910461B1/pt
Publication of BRPI0910461B8 publication Critical patent/BRPI0910461B8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/1048—Glycosyltransferases (2.4)
    • C12N9/1081—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y204/00—Glycosyltransferases (2.4)
    • C12Y204/99—Glycosyltransferases (2.4) transferring other glycosyl groups (2.4.99)
    • C12Y204/99006—N-Acetyllactosaminide alpha-2,3-sialyltransferase (2.4.99.6)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Reproductive Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

hormônio de estimulação do folículo (fhs) recombinante incluindo sialilação alfa 2,3 e alfa 2,6, suas preparações e composições farmacêuticas, uso dos mesmos na fabricação de medicamentos, e método de produção do rfsh. a presente invenção refere-se a preparação incluindo fsh recombinante (rfsh).
BRPI0910461A 2008-04-16 2009-04-16 hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso BRPI0910461B8 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4542408P 2008-04-16 2008-04-16
US61/045,424 2008-04-16
EP08251528 2008-04-25
EP08251528.9 2008-04-25
PCT/GB2009/000978 WO2009127826A1 (en) 2008-04-16 2009-04-16 Recombinant fsh including alpha 2,3- and alpha 2,6-sialylation

Publications (4)

Publication Number Publication Date
BRPI0910461A2 BRPI0910461A2 (pt) 2018-03-27
BRPI0910461A8 BRPI0910461A8 (pt) 2018-10-16
BRPI0910461B1 BRPI0910461B1 (pt) 2021-02-23
BRPI0910461B8 true BRPI0910461B8 (pt) 2021-05-25

Family

ID=39717519

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0910461A BRPI0910461B8 (pt) 2008-04-16 2009-04-16 hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso

Country Status (29)

Country Link
US (6) US8951967B2 (pt)
EP (7) EP4015527B1 (pt)
JP (7) JP2011519359A (pt)
KR (5) KR20160056960A (pt)
CN (3) CN105906702A (pt)
AR (1) AR071479A1 (pt)
AU (5) AU2009237479B2 (pt)
BR (1) BRPI0910461B8 (pt)
CA (1) CA2725257A1 (pt)
CY (1) CY1115413T1 (pt)
DK (6) DK3045471T3 (pt)
ES (5) ES2629392T3 (pt)
FI (4) FI3098234T3 (pt)
FR (3) FR17C1020I2 (pt)
HR (5) HRP20250313T1 (pt)
HU (9) HUE068565T2 (pt)
IL (2) IL208538A (pt)
LT (8) LT3045471T (pt)
MX (3) MX2010011343A (pt)
NO (4) NO2017025I1 (pt)
NZ (1) NZ588381A (pt)
PL (6) PL3144318T3 (pt)
PT (6) PT2268666E (pt)
RU (3) RU2537268C2 (pt)
SA (1) SA109300228B1 (pt)
SI (6) SI4015527T1 (pt)
TW (1) TWI488640B (pt)
WO (1) WO2009127826A1 (pt)
ZA (1) ZA201007373B (pt)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
WO2012016576A1 (en) * 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
EP2628797B1 (en) 2010-10-15 2016-07-13 JCR Pharmaceuticals CO., LTD. Method for producing glycoprotein having mannose residue as non-reducing end of sugar chain
WO2012131306A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) * 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
WO2013093760A2 (en) * 2011-12-19 2013-06-27 Grifols, S.A. Compositions, methods, and kits for preparing sialylated recombinant proteins
EP2848687B1 (en) * 2012-04-27 2017-09-13 JCR Pharmaceuticals Co., Ltd. Novel expression vector
EP2824176A1 (en) 2013-07-11 2015-01-14 Siamed'xpress Methods for producing sialylated therapeutic proteins
JP6652334B2 (ja) 2014-05-31 2020-02-19 Ｊｃｒファーマ株式会社 ウリジンとｎ−アセチル−ｄ−マンノサミンとを含有する培地
CN107429237B (zh) * 2014-12-22 2021-09-28 豪夫迈·罗氏有限公司 Cmp依赖性的唾液酸酶活性
HUE054300T2 (hu) 2015-04-17 2021-08-30 Ferring Bv FSH-t tartalmazó, meddõség kezelésére szolgáló készítmény
MX381279B (es) 2015-06-26 2025-03-12 Ferring Bv Métodos de purificación y/o inactivación viral.
EP3205719A1 (en) * 2016-02-15 2017-08-16 CEVEC Pharmaceuticals GmbH Cell lines for producing recombinant glycoproteins with di-antennary n-glycans, methods using the same, and recombinant glycoproteins
GB201603280D0 (en) 2016-02-24 2016-04-13 Ferring Bv Stable liquid gonadotropin formulation
EP3382014A1 (en) * 2017-03-29 2018-10-03 CEVEC Pharmaceuticals GmbH Recombinant glycoproteins with reduced antennary fucosylation
EP3441471A1 (en) 2017-08-08 2019-02-13 CEVEC Pharmaceuticals GmbH Use of constitutively active variants of growth factor receptors as selection makers for the generation of stable producer cell lines
CN120617484A (zh) 2017-09-01 2025-09-12 辉凌公司 用于受控的卵巢刺激的组合物
US20210038694A1 (en) 2018-04-30 2021-02-11 Ferring B.V. Composition for controlled ovarian stimulation
TWI846743B (zh) 2018-10-17 2024-07-01 荷蘭商菲林公司 用於控制性卵巢刺激之組成物及方法
WO2021081670A1 (en) * 2019-11-01 2021-05-06 The University Of British Columbia Compositions and methods for sialylated mucin-type o-glycosylation of therapeutic proteins
TW202237173A (zh) 2020-12-09 2022-10-01 荷蘭商菲林公司 用於受控的卵巢刺激之組成物及方法
KR20240167660A (ko) 2022-04-01 2024-11-27 훼링 비.브이. 불임의 치료를 위한 혼합 프로토콜
KR20250016113A (ko) 2022-05-26 2025-02-03 훼링 비.브이. 남성 불임 치료를 위한 조성물 및 방법
AU2023302100A1 (en) 2022-07-08 2025-01-02 Ferring B.V. Compositions and methods for intrauterine insemination (iui)
AR133300A1 (es) 2023-07-20 2025-09-17 Ferring Bv Micropartículas cargadas con fármaco de liberación prolongada

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1206302B (it) 1987-06-26 1989-04-14 Serono Cesare Ist Ricerca Ormone follicolo-stimolante urinario
US5541083A (en) 1989-10-24 1996-07-30 The Regents Of The University Of California Method for producing secretable glycosyltransferases and other golgi processing enzymes
KR100470180B1 (ko) 1995-06-15 2005-02-04 크루셀 홀란드 비.브이. 유전자 요법에 사용할 수 있는 인간의 재조합아데노바이러스 패키징 시스템
JP3559652B2 (ja) * 1996-06-25 2004-09-02 グローリー工業株式会社 売上精算システムの管理装置
TW518235B (en) * 1997-01-15 2003-01-21 Akzo Nobel Nv A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage
NZ336780A (en) 1997-01-16 2000-12-22 Neose Technologies Inc In vitro sialylation of glycoproteins
JPH1111665A (ja) 1997-06-28 1999-01-19 Shibuya Kogyo Co Ltd 無菌エア搬送コンベヤ装置
TWI235158B (en) * 1997-09-01 2005-07-01 Kirin Brewery Human thrombopoietin produced by human established cell lines, processes foe preparing the same, and pharmaceutical composition comprising the same
EP1176976B2 (en) 1999-05-07 2015-10-21 Laboratoires Serono SA Use of lh administered in mid- or late-follicular phase for the treatment of anovulatory women
JP2002011665A (ja) 2000-06-28 2002-01-15 Sintokogio Ltd ショットブラスト装置モニタシステム
IL140110A0 (en) 2000-12-05 2002-02-10 Applied Research Systems Improvement of homogeneity and secretion of recombinant proteins in mammalian systems
UA87433C2 (ru) * 2001-10-22 2009-07-27 Еплайд Рісьорч Системз Ерс Холдінг Н.В. Гонадотропины для стимулирования фолликулогенеза
CN100347306C (zh) 2001-10-29 2007-11-07 克鲁塞尔荷兰公司 生产具有预定的翻译后修饰的蛋白质的方法和手段
JP4480398B2 (ja) 2001-12-07 2010-06-16 クルセル ホランド ベー ヴェー ウイルス、ウイルス分離株及びワクチンの製造方法
US20040248784A1 (en) * 2003-06-03 2004-12-09 Marco Filicori Unitary combinations of FSH and hCG
US20080015142A1 (en) * 2003-12-03 2008-01-17 Defrees Shawn Glycopegylated Follicle Stimulating Hormone
EP1711834B1 (en) 2004-02-04 2010-08-04 Centre National De La Recherche Scientifique Process for screening glycoform-specific antibodies
EP1725673A1 (en) 2004-02-13 2006-11-29 Glycotope Gmbh Sialytated glycoproteins-process conditions and an efficient method for their production
TWI488640B (zh) 2008-04-16 2015-06-21 菲瑞茵國際中心股份有限公司 藥學製劑
TWI532495B (zh) 2009-10-05 2016-05-11 菲瑞茵國際中心股份有限公司 藥學製劑
EP2417982A1 (en) 2010-07-30 2012-02-15 Ferring B.V. Stabilization of gonadotropins
US8790322B2 (en) 2010-08-03 2014-07-29 King Saud University Stoma coat
WO2012016576A1 (en) 2010-08-04 2012-02-09 Glycotope Gmbh Improved recombinant human follicle-stimulating hormone
RS54214B2 (sr) 2010-09-29 2024-02-29 Ferring Bv Smeša za upotrebu u lečenju infertiliteta
WO2012131306A1 (en) 2011-03-31 2012-10-04 Ferring B.V. Pharmaceutical preparation
AR090095A1 (es) 2011-06-06 2014-10-22 Ferring Bv Preparacion farmaceutica que comprende hormona estimulante del foliculo recombinante
JO3092B1 (ar) 2011-08-08 2017-03-15 Ferring Bv مركب لتحفيز مسيطر عليه للمبيض
BR112016023668A2 (pt) 2014-04-18 2017-10-17 Glycotope Gmbh hiperestimulação ovariana controlada com hormônio de estimulação de folículo humano recombinante aperfeiçoado

Also Published As

Publication number Publication date
PL2268666T3 (pl) 2014-08-29
BRPI0910461B1 (pt) 2021-02-23
PL3045471T3 (pl) 2017-10-31
DK3098234T3 (da) 2024-10-21
AU2017225020B2 (en) 2019-11-14
LTPA2017029I1 (lt) 2017-10-10
RU2682270C2 (ru) 2019-03-18
RU2745557C3 (ru) 2021-12-10
LT4015527T (lt) 2025-04-10
PT3144318T (pt) 2020-11-04
SI3098234T1 (sl) 2024-10-30
JP6486310B2 (ja) 2019-03-20
JP2011519359A (ja) 2011-07-07
JP2022031652A (ja) 2022-02-22
JP2020040956A (ja) 2020-03-19
HRP20250313T1 (hr) 2025-05-09
HUS1700036I1 (hu) 2017-10-30
JP6762916B2 (ja) 2020-09-30
MX2010011343A (es) 2011-01-20
PL4015527T3 (pl) 2025-05-26
NO2025006I1 (no) 2025-01-16
IL230571A (en) 2015-11-30
PL2808340T3 (pl) 2017-02-28
SA109300228B1 (ar) 2014-04-08
NZ588381A (en) 2012-05-25
DK2268666T3 (da) 2014-05-12
DK2808340T3 (en) 2016-12-05
CY1115413T1 (el) 2017-01-04
EP2808340A1 (en) 2014-12-03
FR25C1003I1 (fr) 2025-02-28
EP3098234B1 (en) 2024-07-31
US9546204B2 (en) 2017-01-17
EP2808340B1 (en) 2016-08-17
US9771407B2 (en) 2017-09-26
AU2017204259B2 (en) 2017-08-17
BRPI0910461A8 (pt) 2018-10-16
ES2610277T3 (es) 2017-04-26
HRP20140535T1 (hr) 2014-07-18
US20110105398A1 (en) 2011-05-05
MX355457B (es) 2018-04-19
FIC20250003I1 (fi) 2025-01-15
DK4015527T3 (da) 2025-04-14
AU2017204258B2 (en) 2017-08-17
BRPI0910461A2 (pt) 2018-03-27
SI2808340T1 (sl) 2016-12-30
EP4015527B1 (en) 2025-01-22
CN105906703A (zh) 2016-08-31
FR17C1020I1 (pt) 2020-04-10
HUE033830T2 (en) 2018-01-29
FIC20250025I1 (fi) 2025-07-11
PT2808340T (pt) 2016-11-21
RU2537268C2 (ru) 2014-12-27
IL208538A0 (en) 2010-12-30
JP2024038000A (ja) 2024-03-19
LT3098234T (lt) 2024-09-10
DK3045471T3 (en) 2017-06-26
SI2268666T1 (sl) 2014-07-31
HRP20241187T1 (hr) 2024-12-06
AU2009237479B2 (en) 2014-05-15
HUE068565T2 (hu) 2025-01-28
EP2268666B1 (en) 2014-03-12
US11952407B2 (en) 2024-04-09
HUE030652T2 (en) 2017-05-29
LTPA2025525I1 (pt) 2025-07-25
US20160347811A1 (en) 2016-12-01
JP2015120696A (ja) 2015-07-02
US10995128B2 (en) 2021-05-04
US20180079794A1 (en) 2018-03-22
PT3098234T (pt) 2024-10-21
RU2014141994A (ru) 2016-05-10
FR17C1020I2 (fr) 2020-04-10
JP2017060476A (ja) 2017-03-30
LT2808340T (lt) 2016-11-10
JP2018021037A (ja) 2018-02-08
KR20110005863A (ko) 2011-01-19
PT4015527T (pt) 2025-04-10
AU2017225020A1 (en) 2017-09-28
NO2017025I1 (no) 2017-06-06
HUS1700024I1 (hu) 2017-06-28
PT3045471T (pt) 2017-06-14
FI3098234T3 (fi) 2024-10-31
US20210332099A1 (en) 2021-10-28
ZA201007373B (en) 2011-06-29
NO2017050I1 (no) 2017-09-28
AU2014203277A1 (en) 2014-07-24
LTPA2017018I1 (lt) 2017-06-26
HUE071059T2 (hu) 2025-07-28
CN102066414A (zh) 2011-05-18
HUS2500008I1 (hu) 2025-02-28
AU2017204259A1 (en) 2017-07-20
MX348622B (es) 2017-06-22
HRP20161520T1 (hr) 2016-12-30
KR20170110741A (ko) 2017-10-11
TWI488640B (zh) 2015-06-21
FR25C1025I1 (fr) 2025-09-19
SI3045471T1 (sl) 2017-07-31
AU2009237479A1 (en) 2009-10-22
HUS2500029I1 (hu) 2025-07-28
IL208538A (en) 2014-03-31
RU2014141994A3 (pt) 2018-05-28
RU2745557C1 (ru) 2021-03-29
SI4015527T1 (sl) 2025-05-30
LTPA2025505I1 (pt) 2025-02-10
SI3144318T1 (sl) 2020-12-31
AU2014203277C1 (en) 2017-07-27
EP3144318B1 (en) 2020-09-23
HUS1700025I1 (hu) 2017-06-28
ES2989729T3 (es) 2024-11-27
HK1199039A1 (en) 2015-06-19
HUE030652T4 (en) 2017-09-28
AU2014203277B2 (en) 2017-04-06
PL3144318T3 (pl) 2021-02-08
EP3144318A1 (en) 2017-03-22
EP3098234A1 (en) 2016-11-30
CN105906702A (zh) 2016-08-31
JP7316905B2 (ja) 2023-07-28
HRP20170958T1 (hr) 2017-09-22
KR101622944B1 (ko) 2016-05-23
KR102108377B1 (ko) 2020-05-08
KR20160056960A (ko) 2016-05-20
DK3144318T3 (da) 2020-12-07
ES2629392T3 (es) 2017-08-09
WO2009127826A1 (en) 2009-10-22
US8951967B2 (en) 2015-02-10
AU2017204258A1 (en) 2017-07-20
CA2725257A1 (en) 2009-10-22
AR071479A1 (es) 2010-06-23
US20150065695A1 (en) 2015-03-05
NO2025032I1 (no) 2025-07-14
US20240327487A1 (en) 2024-10-03
LT3045471T (lt) 2017-07-10
EP3045471B1 (en) 2017-03-29
ES2468318T3 (es) 2014-06-16
PT2268666E (pt) 2014-06-25
EP2268666A1 (en) 2011-01-05
HK1146284A1 (en) 2011-05-20
EP4015527A1 (en) 2022-06-22
KR20180095140A (ko) 2018-08-24
EP3045471A1 (en) 2016-07-20
KR20190092608A (ko) 2019-08-07
RU2010141908A (ru) 2012-05-27
PL3098234T3 (pl) 2025-01-07
US12516094B2 (en) 2026-01-06
FI4015527T3 (fi) 2025-04-29
ES3023526T3 (en) 2025-06-02
TW200948378A (en) 2009-12-01
EP2722339A1 (en) 2014-04-23

Similar Documents

Publication Publication Date Title
BRPI0910461A8 (pt) hormônio de estimulação do folículo recombinante, sua composição farmacêutica, seu método de produção e seu uso.
BRPI0805826B8 (pt) compostos espiro-substituídos, composição farmacêutica e uso
CL2007003635A1 (es) Compuestos derivados de 6-amino-purin-8-ona; proceso de preparacion; composicion farmaceutica; proceso para preparar la composicion farmaceutica; y uso en el tratamiento de enfermedades alergicas, virales o cancer.
MX2019012081A (es) Proteina de fusion del factor de crecimiento 21 de fibroblastos humanos (hfgf21), metodo de preparacion de la misma y su uso.
EP2390265A3 (en) Insulinotropic peptide derivative wherein its N-terminal amino acid is modified
WO2011144673A3 (en) Long - acting formulations of insulins
CL2012001336A1 (es) Composicion farmaceutica solida de daptomicina preparada por liofilizacion de una solucion acuosa que comprende daptomicina y al menos un excipiente seleccionado de glicina y un azucar no reductor con un ph de 6,5-7,5; producto farmaceutico; metodo de fabricacion; uso para tratar infecciones bacterianas.
BR112014029966A2 (pt) proteínas de fator de crescimento de fibroblasto 21
CL2007002610A1 (es) Compuestos derivados de bipiridina sustituida; procedimiento de preparacion; composicion farmaceutica; y uso en el tratamiento y/o la profilaxis de enfermedades tales como hipertonia, diabetes, infarto de miocardio, entre otras.
CL2009002206A1 (es) Compuestos derivados de pirrolo -(2-3-d]-pirimidin-7(6h)-tetrahidrofuran-2-il fosfonamidato, composicion farmaceutica; y su uso en el tratamiento de enfermedades virales.
NZ586588A (en) Formulation of ( follice stimulating hormone) fsh and varients with benzalkonium chloride and benzyl alcohol
UY29410A1 (es) Composiciones farmacéuticas en base a metilamidas del ácido 4-(4-/-3(-4-cloro-3-trifluorometifenil)ureido)fenoxi)piridin-2-carboxílico, procedimiento de preparación y aplicaciones.
BR112015032559A8 (pt) cerâmica odontológica de zircônia, artigo odontológico, e seu método de fabricação
CL2007000161A1 (es) Compuestos derivados de 2,4-dioxoimidazolidina sustituida, inhibidores de proteinas cinasas; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer.
BR112012027759A2 (pt) Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
CL2008003537A1 (es) Compuestos derivados de 2-amino-pirimidina, antagonistas de receptores h4; procedimiento de preparacion; composicion farmaceutica que comprende a dicho compuesto; y uso del compuesto en el tratamiento de una enfermedad alergica, inmunologica o inflamatoria o dolor.
ECSP034772A (es) Antagonistas de mch y su uso en el tratamiento de obesidad
EP3501546A3 (de) Cystein-wirkstoff konjugate und ihre verwendung
NZ702801A (en) Treatment of sanfilippo syndrome type b
BRPI0618488A2 (pt) proteìnas de fusão de ìntron de fator de crescimento de hepatócito
CO5640037A2 (es) Derivados de la quinazolina para el tratamiento del cancer
CR10092A (es) Nuevos derivados de furopirimidina aciclicos sustituidos y su uso
UA117480C2 (uk) Лікування цукрового діабету за допомогою складу інсуліну тривалої дії
AR054525A1 (es) Composiciones y metodos para eltratamiento de sintomas relacionados con el ciclo
BRPI1012666B8 (pt) cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 23/02/2021, OBSERVADAS AS CONDICOES LEGAIS.

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 16/04/2009 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF